Merck’s COVID antiviral may be linked to virus mutations, study finds
Published
An antiviral drug that was granted an emergency use authorization by the U.S. Food and Drug Administration in December 2021 may be linked to mutations in the virus, according to a new study released on Monday. Molnupiravir, an antiviral developed by Merck & Co. MRK, , works by causing mutations in…
#merckco #nature #merck #ryanhisner #universityofcapetown #southafrica